Literature DB >> 1427021

Family study of alpha 1-antitrypsin deficiency: effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits.

E K Silverman1, M A Province, E J Campbell, J A Pierce, D C Rao.   

Abstract

To gain insight into the variable expression of lung disease in alpha 1-antitrypsin (alpha 1AT) deficiency, five quantitative variables including forced expiratory volume at 1 sec (FEV1), forced expiratory flow rate between 25 and 75% of forced vital capacity (FEF25-75), total serum alpha 1AT, oxidized serum alpha 1AT, and total serum immunoglobulin E (IgE) were measured in alpha 1AT deficient individuals and their families. The effect of a known, measured genotype (the Pi type) was estimated for each quantitative trait; the influence of mode of case ascertainment on the measured genotype effect was also assessed. These analyses showed that total alpha 1AT levels are strongly influenced by Pi type; IgE levels are unaffected by Pi type; and FEV1, FEF25-75, and oxidized alpha 1AT are moderately influenced by Pi type. The effect of genotype-by-environment interaction between Pi type and pack-years of cigarette smoking on the five quantitative phenotypes was studied using an analysis of covariance. Significant Pi x pack-years interaction was evident for FEV1, but this effect is confounded in this data set with the Pi x age interaction. Probands who were ascertained because they had chronic obstructive pulmonary disease (COPD) do not demonstrate the significant Pi x pack-years interaction effect of the Pi x pack-years subjects ascertained for other reasons demonstrate. The effect of the Pi x pack-years interaction on FEV1 was no longer significant on a transformed scale, (FEVf12,) thus providing an additive scale for future data analysis. The increased sensitivity of Pi MZ individuals in our sample to cigarette smoking reduced the Pi x packs-years interaction effect on FEF25-75 to borderline significance. This investigation has provided an opportunity to incorporate both measured genotype and genotype-by-environment interaction analyses into the study of the variable expression of lung disease in Pi Z individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1427021     DOI: 10.1002/gepi.1370090504

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  13 in total

1.  Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups.

Authors:  Marilyn G Foreman; Carla Wilson; Dawn L DeMeo; Craig P Hersh; Terri H Beaty; Michael H Cho; John Ziniti; Douglas Curran-Everett; Gerard Criner; John E Hokanson; Mark Brantly; Farshid N Rouhani; Robert A Sandhaus; James D Crapo; Edwin K Silverman
Journal:  Ann Am Thorac Soc       Date:  2017-08

2.  Genetic determinants of emphysema distribution in the national emphysema treatment trial.

Authors:  Dawn L DeMeo; Craig P Hersh; Eric A Hoffman; Augusto A Litonjua; Ross Lazarus; David Sparrow; Joshua O Benditt; Gerard Criner; Barry Make; Fernando J Martinez; Paul D Scanlon; Frank C Sciurba; James P Utz; John J Reilly; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2007-03-15       Impact factor: 21.405

3.  Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.

Authors:  N Seersholm; A Kok-Jensen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

4.  Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency.

Authors:  P J Castaldi; D L DeMeo; D M Kent; E J Campbell; A F Barker; M L Brantly; E Eden; N G McElvaney; S I Rennard; J M Stocks; J K Stoller; C Strange; G Turino; R A Sandhaus; J L Griffith; E K Silverman
Journal:  Am J Epidemiol       Date:  2009-09-02       Impact factor: 4.897

Review 5.  Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk.

Authors:  D L DeMeo; E K Silverman
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

6.  Pleiotropic associations of heterozygosity for the SERPINA1 Z allele in the UK Biobank.

Authors:  Katherine A Fawcett; Kijoung Song; Guoqing Qian; Aliki-Eleni Farmaki; Richard Packer; Catherine John; Nick Shrine; Raquel Granell; Sue Ring; Nicholas J Timpson; Laura M Yerges-Armstrong; Richard Eastell; Louise V Wain; Robert A Scott; Martin D Tobin; Ian P Hall
Journal:  ERJ Open Res       Date:  2021-05-10

7.  A systematic analysis of protein-altering exonic variants in chronic obstructive pulmonary disease.

Authors:  Matthew Moll; Victoria E Jackson; Bing Yu; Megan L Grove; Stephanie J London; Sina A Gharib; Traci M Bartz; Colleen M Sitlani; Josée Dupuis; George T O'Connor; Hanfei Xu; Patricia A Cassano; Bonnie Kaufmann Patchen; Woo Jin Kim; Jinkyeong Park; Kun Hee Kim; Buhm Han; R Graham Barr; Ani Manichaikul; Jennifer N Nguyen; Stephen S Rich; Lies Lahousse; Natalie Terzikhan; Guy Brusselle; Phuwanat Sakornsakolpat; Jiangyuan Liu; Christopher J Benway; Ian P Hall; Martin D Tobin; Louise V Wain; Edwin K Silverman; Michael H Cho; Brian D Hobbs
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-04-28       Impact factor: 6.011

Review 8.  Genetics of chronic obstructive pulmonary disease.

Authors:  Carola Seifart; Alexandra Plagens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

9.  The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém).

Authors:  Judith Bellemare; Nathalie Gaudreault; Kim Valette; Irene Belmonte; Alexa Nuñez; Marc Miravitlles; François Maltais; Yohan Bossé
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

10.  Genome-Wide Gene-by-Smoking Interaction Study of Chronic Obstructive Pulmonary Disease.

Authors:  Woori Kim; Dmitry Prokopenko; Phuwanat Sakornsakolpat; Brian D Hobbs; Sharon M Lutz; John E Hokanson; Louise V Wain; Carl A Melbourne; Nick Shrine; Martin D Tobin; Edwin K Silverman; Michael H Cho; Terri H Beaty
Journal:  Am J Epidemiol       Date:  2021-05-04       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.